Ely Benaim - 10 May 2021 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: Chief Medical Officer
Signature: By: /s/ Steven Robbins, Attorney in Fact for Ely Benaim
Issuer symbol: NVCR
Transactions as of: 10 May 2021
Net transactions value: -$667,878
Form type: 4
Filing time: 12 May 2021, 16:15:39 UTC
Next filing: 14 May 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Options Exercise	$87,177	+1,833	+5.5%	$47.56	35,092	10 May 2021	Direct
transaction	NVCR	Ordinary Shares	Sale	$347,628	-1,833	-5.2%	$189.65^*	33,259	10 May 2021	Direct	F1
transaction	NVCR	Ordinary Shares	Sale	$407,427	-2,262	-6.8%	$180.12^*	30,997	11 May 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVCR	Options to Buy Ordinary Shares	Options Exercise	$0	-1,833	-17%	$0.000000	9,165	10 May 2021	Ordinary Shares	1,833	$47.56	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.
F2	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3	Fully vested as of the date hereof.